MrWealthy的个人主页 - 老虎社区

MrWealthy

MrWealthy

暂无个人介绍

IP属地：未知

26关注

0粉丝

0主题

0勋章

2021-06-22

Up up up..

抱歉，原内容已删除

2021-06-15

Let fly to the moon tonight

抱歉，原内容已删除

2021-06-15

Yes all go up

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

2021-06-14

Great 👍

抱歉，原内容已删除

2021-06-14

Nice..

Oatly Divides Analysts Who Love the Story, But Maybe Not Quite Yet

2021-06-14

hello jiayou all..

抱歉，原内容已删除

2021-05-26

Like and comment, please

抱歉，原内容已删除

2021-05-26

Great sharing

抱歉，原内容已删除

2021-05-26

//@MrWealthy: Up up up to the moon

抱歉，原内容已删除

2021-05-26

Take on the ride together ....

抱歉，原内容已删除

2021-05-26

Up up up to the moon

AMC Price Target Raised, Sell Rating Affirmed at Citi

2021-05-13

Good sharing

Lemonade paring market loss after new short call from Muddy Waters

2021-05-13

Amc bravo

3 Compelling Reasons to Avoid AMC Stock

2021-05-13

Great article

Lemonade paring market loss after new short call from Muddy Waters

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583498842755651","uuid":"3583498842755651","gmtCreate":1620492642642,"gmtModify":1620917795829,"name":"MrWealthy","pinyin":"mrwealthy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":26,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":120952794,"gmtCreate":1624293245018,"gmtModify":1634008220182,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Up up up..","listText":"Up up up..","text":"Up up up..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120952794","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187505908,"gmtCreate":1623757580504,"gmtModify":1634028908479,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Let fly to the moon tonight","listText":"Let fly to the moon tonight","text":"Let fly to the moon tonight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/187505908","repostId":"1178091722","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187240224,"gmtCreate":1623756650268,"gmtModify":1634028931120,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Yes all go up","listText":"Yes all go up","text":"Yes all go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187240224","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184357608,"gmtCreate":1623686003204,"gmtModify":1634030056422,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Great 👍","listText":"Great 👍","text":"Great 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184357608","repostId":"1117313016","repostType":4,"isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184357985,"gmtCreate":1623685969847,"gmtModify":1634030056643,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Nice..","listText":"Nice..","text":"Nice..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/184357985","repostId":"2143800737","repostType":4,"repost":{"id":"2143800737","kind":"news","pubTimestamp":1623682510,"share":"https://www.laohu8.com/m/news/2143800737?lang=&edition=full","pubTime":"2021-06-14 22:55","market":"us","language":"en","title":"Oatly Divides Analysts Who Love the Story, But Maybe Not Quite Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2143800737","media":"Investing.com","summary":"Investing.com -- Oat milk anyone? Hm, maybe.\nMost analysts appear to be into the alt-milk drink, whi","content":"<p>Investing.com -- Oat milk anyone? Hm, maybe.</p>\n<p>Most analysts appear to be into the alt-milk drink, while others not so much.</p>\n<p>Shares fell some 3%.</p>\n<p>Piper Sandler is firmly in the buy camp, saying its brand equity and pricing power set it apart and warrant a valuation premium.</p>\n<p>The total addressable market size is \"significant\" and Oatly should continue gaining share, only limited by capacity. It also has solid (buzz term!) ESG credentials, boasting 80% less carbon emissions and 60% less energy usage versus cow's milk, analyst Michael Lavery wrote in a note according to StreetInsider. He set a price target of $30.00.</p>\n<p>Guggenheim also called Oatly a buy, with a $32 price target, similarly calling it \"uniquely positioned with a defensible market position\" thanks to its sustainability focus and a disruptive marketing with a unique “in-your-face” brand message to challenge the status quo, analyst Laurent Grandet said in a note, StreetInsider reported.</p>\n<p>\"In our view, the company is in the early stages of a long-term growth story that could generate double-digit annual sales growth for at least the next 10 years if it continues to invest heavily in capacity expansion,\" Grandet said.</p>\n<p>RBC Capital, meanwhile, initiated coverage at a neutral-equivalent, with a price target of $28. Analyst Nik Modi said, \"Our rating is less about our belief in the Oatly growth story and more about taking a measured approach to stock-picking based on the company’s current growth-related challenges (capacity buildout that could delay profitability timeline).\"</p>\n<p>Exane BNP Paribas (OTC:BNPQY) and Oppenheimer also gave the stock a neutral-equivalent, with the latter citing valuation as a reason to remain on the sidelines, for now.</p>\n<p>Sweden-based Oatly went public in May, raising $1.4 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oatly Divides Analysts Who Love the Story, But Maybe Not Quite Yet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOatly Divides Analysts Who Love the Story, But Maybe Not Quite Yet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oatly-divides-analysts-love-story-103010024.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Oat milk anyone? Hm, maybe.\nMost analysts appear to be into the alt-milk drink, while others not so much.\nShares fell some 3%.\nPiper Sandler is firmly in the buy camp, saying its ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oatly-divides-analysts-love-story-103010024.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLY":"Oatly Group AB"},"source_url":"https://finance.yahoo.com/news/oatly-divides-analysts-love-story-103010024.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143800737","content_text":"Investing.com -- Oat milk anyone? Hm, maybe.\nMost analysts appear to be into the alt-milk drink, while others not so much.\nShares fell some 3%.\nPiper Sandler is firmly in the buy camp, saying its brand equity and pricing power set it apart and warrant a valuation premium.\nThe total addressable market size is \"significant\" and Oatly should continue gaining share, only limited by capacity. It also has solid (buzz term!) ESG credentials, boasting 80% less carbon emissions and 60% less energy usage versus cow's milk, analyst Michael Lavery wrote in a note according to StreetInsider. He set a price target of $30.00.\nGuggenheim also called Oatly a buy, with a $32 price target, similarly calling it \"uniquely positioned with a defensible market position\" thanks to its sustainability focus and a disruptive marketing with a unique “in-your-face” brand message to challenge the status quo, analyst Laurent Grandet said in a note, StreetInsider reported.\n\"In our view, the company is in the early stages of a long-term growth story that could generate double-digit annual sales growth for at least the next 10 years if it continues to invest heavily in capacity expansion,\" Grandet said.\nRBC Capital, meanwhile, initiated coverage at a neutral-equivalent, with a price target of $28. Analyst Nik Modi said, \"Our rating is less about our belief in the Oatly growth story and more about taking a measured approach to stock-picking based on the company’s current growth-related challenges (capacity buildout that could delay profitability timeline).\"\nExane BNP Paribas (OTC:BNPQY) and Oppenheimer also gave the stock a neutral-equivalent, with the latter citing valuation as a reason to remain on the sidelines, for now.\nSweden-based Oatly went public in May, raising $1.4 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184355081,"gmtCreate":1623685874143,"gmtModify":1634030058615,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"hello jiayou all..","listText":"hello jiayou all..","text":"hello jiayou all..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184355081","repostId":"2143738859","repostType":4,"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136435834,"gmtCreate":1622034952028,"gmtModify":1634184488642,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Like and comment, please&nbsp;","listText":"Like and comment, please&nbsp;","text":"Like and comment, please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/136435834","repostId":"2138110551","repostType":4,"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136495147,"gmtCreate":1622034261889,"gmtModify":1634184496014,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Great sharing","listText":"Great sharing","text":"Great sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/136495147","repostId":"2138117769","repostType":4,"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136492524,"gmtCreate":1622034220168,"gmtModify":1634184496621,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3583498842755651\">@MrWealthy</a>: Up up up to the moon","listText":"//<a href=\"https://laohu8.com/U/3583498842755651\">@MrWealthy</a>: Up up up to the moon","text":"//@MrWealthy: Up up up to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136492524","repostId":"1159103819","repostType":4,"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136953563,"gmtCreate":1621991396152,"gmtModify":1634184927872,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Take on the ride together ....","listText":"Take on the ride together ....","text":"Take on the ride together ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136953563","repostId":"1159103819","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136950370,"gmtCreate":1621991301790,"gmtModify":1634184929558,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Up up up to the moon","listText":"Up up up to the moon","text":"Up up up to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136950370","repostId":"1159103819","repostType":4,"repost":{"id":"1159103819","kind":"news","pubTimestamp":1621990785,"share":"https://www.laohu8.com/m/news/1159103819?lang=&edition=full","pubTime":"2021-05-26 08:59","market":"us","language":"en","title":"AMC Price Target Raised, Sell Rating Affirmed at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=1159103819","media":"The Street","summary":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the the","content":"<blockquote>\n AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n</blockquote>\n<p>AMC Entertainment&nbsp;(<b>AMC</b>) -Get Report&nbsp;shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.</p>\n<p>To be sure, he kept his sell rating.</p>\n<p>AMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.</p>\n<p>As for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.</p>\n<p>AMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.</p>\n<p>In other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.</p>\n<p>AMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"</p>\n<p>AMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.</p>\n<p>AMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.</p>\n<p>On May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Price Target Raised, Sell Rating Affirmed at Citi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Price Target Raised, Sell Rating Affirmed at Citi\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet ...</p>\n\n<a href=\"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159103819","content_text":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.\nTo be sure, he kept his sell rating.\nAMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.\nAs for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.\nAMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.\nIn other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.\nAMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"\nAMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.\nAMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.\nOn May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198916846,"gmtCreate":1620918017485,"gmtModify":1634195276168,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/198916846","repostId":"1120393789","repostType":4,"repost":{"id":"1120393789","kind":"news","pubTimestamp":1620917058,"share":"https://www.laohu8.com/m/news/1120393789?lang=&edition=full","pubTime":"2021-05-13 22:44","market":"us","language":"en","title":"Lemonade paring market loss after new short call from Muddy Waters","url":"https://stock-news.laohu8.com/highlight/detail?id=1120393789","media":"seekingalpha","summary":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerabilit","content":"<p>Lemonade now&nbsp;up 2%,&nbsp;hours&nbsp;ago,&nbsp;on a&nbsp;short call from Muddy Waters that alleges a securityvulnerability with the company.</p><p><img src=\"https://static.tigerbbs.com/01f8da73a2adc99f0e8f04cc034d6170\" tg-width=\"769\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p><p>Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.</p><p>Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"</p><p>Lemonade didn't immediately respond to Seeking Alpha request for comment.</p><p>Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.</p><p>Lemonadeshort interest 19%of float.</p><p>Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lemonade paring market loss after new short call from Muddy Waters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLemonade paring market loss after new short call from Muddy Waters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially ...</p>\n\n<a href=\"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc."},"source_url":"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1120393789","content_text":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"Lemonade didn't immediately respond to Seeking Alpha request for comment.Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.Lemonadeshort interest 19%of float.Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198919992,"gmtCreate":1620917792316,"gmtModify":1634195278750,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Amc bravo","listText":"Amc bravo","text":"Amc bravo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/198919992","repostId":"1186620588","repostType":4,"repost":{"id":"1186620588","kind":"news","pubTimestamp":1620915120,"share":"https://www.laohu8.com/m/news/1186620588?lang=&edition=full","pubTime":"2021-05-13 22:12","market":"us","language":"en","title":"3 Compelling Reasons to Avoid AMC Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1186620588","media":"InvestorPlace","summary":"Poor fundamentals, heavy dilution and increasing competition make AMC stock a risky post-pandemic pl","content":"<blockquote><b>Poor fundamentals, heavy dilution and increasing competition make AMC stock a risky post-pandemic play.</b></blockquote><p>The pandemic hasn’t been easy for anyone, but it has been the toughest for<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>). The theatre chain has faced several problems over the past year, and after being a target of Reddit’s short squeeze, AMC stock has consistently been volatile.</p><p><img src=\"https://static.tigerbbs.com/8f6efae0485c393819ccba85f126d7f7\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Helen89 / Shutterstock.com</p><p>The stock went from $2 to hit a high of $20 in January 2021 but has fallen since then. It continues to attract speculative interest and has risen significantly since the beginning of 2021. AMC stock is currently exchanging hands at $10.34, as of midday May 12, but I do not think the stock is worth your money nor your time. There is a lot going wrong for AMC and it may have been able to avoid bankruptcy, but its fundamentals are shaky. With that in mind, let’s take a look at the 3 reasons to avoid AMC stock.</p><p><b>Poor Fundamentals</b></p><p>AMC Entertainment recentlyreported the first quarter earnings&nbsp;and it incurred a loss of $567.2 million. Despite reopening most of its treaters, the company reported a loss of $1.42 a share which is higher than the $1.31 expected by the analysts. The revenue stood at $148.3 million which is a huge decline from the first quarter in 2020 while the cash balance was $813 million.</p><p>Even before the pandemic, the company’s business was flat. Even if we assume that moviegoers head to the theatres in the coming quarter, we must not expect impressive sales or revenue numbers.</p><p>It may take the entire year for the company to report strong revenue numbers. Considering the current capacity restraints, it is hard to expect the company to generate higher revenue and sales.</p><p><b>Heavy dilution</b></p><p>To survive the pandemic, AMC Entertainment has been burning a significant amount of cash and it has raised the cash through dilution. It may work well for the company but is harming the shareholders.</p><p>The company had earlier proposed the issue of 500 shares but scrapped it for the year and is planning to issue another 43 million shares. The company has quadrupled the share count in 2020. With each dilution, shareholders are losing value and investors are losing interest in the company. If AMC continues todilute the shares, there will be fewer takers for AMC stock in the future because it is a no-win scenario for investors.</p><p><b>Stiff competition</b></p><p>One cannot deny the fact that AMC Entertainment has stiff competition to handle. With a surge in OTT platforms and changing preferences of consumers, the theatre chain may not enjoy full movie rights from studios. Its biggest competition is with<b>Disney</b>&nbsp;(NYSE:<b><u>DIS</u></b>) who is making strong moves to continue using the Disney+ streaming service for new movies. It has entered into anagreement with Sonyfor the streaming of movies after the theatrical releases.</p><p>Consumers will be less willing to pay for a movie they can watch from the comfort of their homes. Several OTT platforms will be directly releasing movies without giving them a theatrical launch. Most of us are used to spending time at home and we have become accustomed to enjoying entertainment on our couches. Who would be willing to pay for a movie that is available at your home at your convenience?</p><p><b>The bottom line on AMC stock</b></p><p>If you are looking for a post-pandemic play, avoid AMC stock. There are several other options to consider.</p><p>Weak financials and changing consumer preferences make AMC a poor choice. The company will continue to face competition in the future, and will have to fight for a smaller number of customers to generate revenues. It could maintain a presence in the market and may even go high based on speculation, but it will not last long enough to generate higher revenues.</p><p>In short, avoid AMC stock this year.</p><p><i>On the date of publication, Vandita Jadeja did not have (either directly or indirectly) any positions in the securities mentioned in this article.</i></p><p>AMC rose nearly 13% in early market trading.</p><p><img src=\"https://static.tigerbbs.com/b44c7994990a17ad22e1db8d6a10a4b8\" tg-width=\"769\" tg-height=\"564\"></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Compelling Reasons to Avoid AMC Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Compelling Reasons to Avoid AMC Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/3-compelling-reasons-to-avoid-amc-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Poor fundamentals, heavy dilution and increasing competition make AMC stock a risky post-pandemic play.The pandemic hasn’t been easy for anyone, but it has been the toughest forAMC Entertainment(NYSE:...</p>\n\n<a href=\"https://investorplace.com/2021/05/3-compelling-reasons-to-avoid-amc-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/05/3-compelling-reasons-to-avoid-amc-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186620588","content_text":"Poor fundamentals, heavy dilution and increasing competition make AMC stock a risky post-pandemic play.The pandemic hasn’t been easy for anyone, but it has been the toughest forAMC Entertainment(NYSE:AMC). The theatre chain has faced several problems over the past year, and after being a target of Reddit’s short squeeze, AMC stock has consistently been volatile.Source: Helen89 / Shutterstock.comThe stock went from $2 to hit a high of $20 in January 2021 but has fallen since then. It continues to attract speculative interest and has risen significantly since the beginning of 2021. AMC stock is currently exchanging hands at $10.34, as of midday May 12, but I do not think the stock is worth your money nor your time. There is a lot going wrong for AMC and it may have been able to avoid bankruptcy, but its fundamentals are shaky. With that in mind, let’s take a look at the 3 reasons to avoid AMC stock.Poor FundamentalsAMC Entertainment recentlyreported the first quarter earnings and it incurred a loss of $567.2 million. Despite reopening most of its treaters, the company reported a loss of $1.42 a share which is higher than the $1.31 expected by the analysts. The revenue stood at $148.3 million which is a huge decline from the first quarter in 2020 while the cash balance was $813 million.Even before the pandemic, the company’s business was flat. Even if we assume that moviegoers head to the theatres in the coming quarter, we must not expect impressive sales or revenue numbers.It may take the entire year for the company to report strong revenue numbers. Considering the current capacity restraints, it is hard to expect the company to generate higher revenue and sales.Heavy dilutionTo survive the pandemic, AMC Entertainment has been burning a significant amount of cash and it has raised the cash through dilution. It may work well for the company but is harming the shareholders.The company had earlier proposed the issue of 500 shares but scrapped it for the year and is planning to issue another 43 million shares. The company has quadrupled the share count in 2020. With each dilution, shareholders are losing value and investors are losing interest in the company. If AMC continues todilute the shares, there will be fewer takers for AMC stock in the future because it is a no-win scenario for investors.Stiff competitionOne cannot deny the fact that AMC Entertainment has stiff competition to handle. With a surge in OTT platforms and changing preferences of consumers, the theatre chain may not enjoy full movie rights from studios. Its biggest competition is withDisney (NYSE:DIS) who is making strong moves to continue using the Disney+ streaming service for new movies. It has entered into anagreement with Sonyfor the streaming of movies after the theatrical releases.Consumers will be less willing to pay for a movie they can watch from the comfort of their homes. Several OTT platforms will be directly releasing movies without giving them a theatrical launch. Most of us are used to spending time at home and we have become accustomed to enjoying entertainment on our couches. Who would be willing to pay for a movie that is available at your home at your convenience?The bottom line on AMC stockIf you are looking for a post-pandemic play, avoid AMC stock. There are several other options to consider.Weak financials and changing consumer preferences make AMC a poor choice. The company will continue to face competition in the future, and will have to fight for a smaller number of customers to generate revenues. It could maintain a presence in the market and may even go high based on speculation, but it will not last long enough to generate higher revenues.In short, avoid AMC stock this year.On the date of publication, Vandita Jadeja did not have (either directly or indirectly) any positions in the securities mentioned in this article.AMC rose nearly 13% in early market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198937930,"gmtCreate":1620917706020,"gmtModify":1634195279996,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583498842755651","authorIdStr":"3583498842755651"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/198937930","repostId":"1120393789","repostType":4,"repost":{"id":"1120393789","kind":"news","pubTimestamp":1620917058,"share":"https://www.laohu8.com/m/news/1120393789?lang=&edition=full","pubTime":"2021-05-13 22:44","market":"us","language":"en","title":"Lemonade paring market loss after new short call from Muddy Waters","url":"https://stock-news.laohu8.com/highlight/detail?id=1120393789","media":"seekingalpha","summary":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerabilit","content":"<p>Lemonade now&nbsp;up 2%,&nbsp;hours&nbsp;ago,&nbsp;on a&nbsp;short call from Muddy Waters that alleges a securityvulnerability with the company.</p><p><img src=\"https://static.tigerbbs.com/01f8da73a2adc99f0e8f04cc034d6170\" tg-width=\"769\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p><p>Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.</p><p>Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"</p><p>Lemonade didn't immediately respond to Seeking Alpha request for comment.</p><p>Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.</p><p>Lemonadeshort interest 19%of float.</p><p>Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lemonade paring market loss after new short call from Muddy Waters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLemonade paring market loss after new short call from Muddy Waters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially ...</p>\n\n<a href=\"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc."},"source_url":"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1120393789","content_text":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"Lemonade didn't immediately respond to Seeking Alpha request for comment.Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.Lemonadeshort interest 19%of float.Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":187505908,"gmtCreate":1623757580504,"gmtModify":1634028908479,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Let fly to the moon tonight","listText":"Let fly to the moon tonight","text":"Let fly to the moon tonight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/187505908","repostId":"1178091722","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136495147,"gmtCreate":1622034261889,"gmtModify":1634184496014,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Great sharing","listText":"Great sharing","text":"Great sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/136495147","repostId":"2138117769","repostType":4,"repost":{"id":"2138117769","kind":"news","pubTimestamp":1622033700,"share":"https://www.laohu8.com/m/news/2138117769?lang=&edition=full","pubTime":"2021-05-26 20:55","market":"us","language":"en","title":"Disrupters Are Driving the Car Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2138117769","media":"Kiplinger","summary":"When I was 9, my grandfather gave me a present: my first share of stock. It was a gorgeous, embossed","content":"<p>When I was 9, my grandfather gave me a present: my first share of stock. It was a gorgeous, embossed certificate issued by the Ford Motor (F), which had just gone public on January 18, 1956, at $64.50 a share.</p><p>In 1988, I decided to sell my share, which after splits had become many shares worth $828. Selling at the time turned out to be a good idea. Ford shares peaked in 1999.</p><p>But don’t count Ford out. The drop in revenues from the pandemic was not as bad as expected, and over the past 12 months, the stock has returned 143%; General Motors (GM)&nbsp;has returned 162%.</p><p>Ford and GM, two stodgy companies that have been selling pretty much the same product for more than a century, have felt the shock of an earthshaking disruption of their industry. It's a case of respond or die, and the two companies have responded, though a bit late.</p><p><i>Disruptive innovation</i> is a term coined in 1995 by Harvard Business School professor Clayton Christensen. Most people use the shorthand <i>disruption</i> to mean a general shake-up in an industry. But Christensen, who died last year, had a more precise definition: \"a process whereby a smaller company with fewer resources is able to successfully challenge established incumbent businesses.\"</p><p>While the incumbents are focused on gradually improving their products to satisfy traditional customers, disrupters target \"overlooked segments, gaining a foothold,\"&nbsp;Christensen wrote.</p><p>Incumbents ignore disrupters because those segments are small or unprofitable. The disrupters then expand their offerings, \"delivering the performance that incumbents'&nbsp;mainstream customers require, while preserving the advantages that drove their early success.\"&nbsp;When mainstream customers start adopting the disrupters'&nbsp;products \"in volume,\"&nbsp;you've got real disruption.</p><h2>Tesla: A Model Disrupter</h2><p>A model disrupter.<b> </b>An upstart called Tesla Motors, now just <b>Tesla </b>(TSLA), fits the Christensen model. The company was launched in 2003, released its first plug-in electric car five years later, and went public two years after that. Elon Musk took his earnings as cofounder of <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings (PYPL)&nbsp;and became an early investor in Tesla; in 2008, he became CEO.</p><p>In 2015, when Christensen’s article from which I'm quoting appeared in the <i>Harvard Business Review, </i>Tesla had two models and it sold 50,000 cars. Sales doubled in two years and reached 500,000 in 2020; this year, the forecast is 800,000 vehicles.</p><p>Tesla is by far the largest global electric vehicle maker, manufacturing four models, including <a href=\"https://laohu8.com/S/AONE\">one</a> with a list price of only $40,120. It's working on a beautiful long-haul truck. Holding Tesla back from even more sales this year is a pandemic-induced shortage of microchips, which should be temporary.</p><p>The incumbents have responded. Last year, Ford said it would invest $11.5 billion in electric vehicles through 2022, producing a zero-emissions Mustang and F-150 truck. In January, GM announced it would phase out petroleum-fueled vehicles and sell only cars and trucks that produce zero emissions.</p><p>I was not a Tesla believer years ago, but I am now. Tesla is still small ($32 billion in revenues last year, compared with GM's $122 billion) and unprofitable. An investment in Bitcoin and sales of regulatory credits to internal-combustion-engine carmakers saved Tesla from showing a loss in the most recent quarter.</p><p>Stocks, however, are priced according to expectations, not history, and Tesla's future looks spectacular. In late 2019, Teslas started rolling out of a $2 billion factory in Shanghai, and in April the company announced a $1 billion factory in Austin, Texas.</p><p>Musk forecasts that Tesla's U.S. market share will rise from 2% today to 10% in 2025, and analysts at <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> project that the company's manufacturing capacity will reach 5.5 million vehicles by 2030. That compares favorably with GM's 6.8 million in 2020.</p><p>Tesla's stock price has become more attractive lately, dropping more than 20% from its January peak, partly because of the chip shortage. Its market capitalization (shares outstanding times price) is $647 billion, or nearly twice as much as GM, Ford and Toyota Motor (TM) combined. In fact, Tesla is the seventh-largest U.S. company by market cap, after five tech giants and Berkshire Hathaway (BRK.B); it's bigger than Walmart (WMT) and JPMorgan Chase (JPM).</p><p>Is this crazy?</p><p>I don't think so. The global auto market is estimated to grow to $9 trillion by 2030.</p><h2>11 More Automotive Innovators</h2><p>Tech is the ignition. Tesla is not the only vehicle disrupter. Technology is front and center in the sector. Small, innovative companies abound, most of them still private. But there are good stocks to buy. One of the largest is the dominant ride-hailing company, <b>Uber</b> (UBER), with a market cap of about $90 billion.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/8A8Qem2IIJaPSIq.9gLx9w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/kiplinger.com/17e6181ced6ec8ec65324c7cf5b6315e\" tg-width=\"845\" tg-height=\"426\" referrerpolicy=\"no-referrer\"></p><p>SOURCE: Morningstar</p><p><b>Veoneer</b>&nbsp;(VNE) is a Swedish company that makes automobile-mounted cameras, systems that assist night driving and other navigation electronics. Sales were hit last year by the pandemic, and the stock trades at less than half its 2018 high.</p><p>Another attractive Swedish firm, <b>Autoliv</b> (ALV), makes auto-safety systems for the global auto industry. Autoliv has been consistently profitable, with a stock that's up by more than half this year. <b>Aptiv</b> (APTV), an Irish maker of sophisticated vehicle electronics, is also highly profitable, with a $38 billion market cap.</p><p>Another company with substantial sales and earnings and a commitment to EVs is <b>BYD</b> (BYDDY), based in Shenzhen, China, with a market cap of $60 billion. BYD (an acronym for “Build Your Dreams”) started as a battery maker and now manufactures electric and internal-combustion vehicles; some of its EVs sell for as little as $9,000. Nearly all of Shenzhen’s 20,000 taxis are BYDs. Part of the appeal of BYD: The stock is down 46% since February, despite consistently rising revenues.</p><p>China is the largest market for EVs, with 1.2 million sales last year. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other Chinese manufacturers to note are<b> Li Auto</b> (LI), whose niche is SUVs, and the larger <b>XPeng</b> (XPEV), which makes SUVs and a four-door sport sedan; Xpeng is also in the ride-hailing business. Both stocks are well priced, having fallen by half in less than six months.</p><p>More risky but worth consideration are some early-stage auto-tech firms.<b> Luminar Technologies</b>&nbsp;(LAZR) makes sensors and software that enable autonomous driving. Luminar had only $14 million in sales last year, but its prospects have earned it a market cap of $7 billion.</p><p><b>QuantumScape</b>&nbsp;(QS) is a lithium-ion battery maker with no sales in 2020 but a market cap of $12 billion. <b><a href=\"https://laohu8.com/S/BEEM\">Beam Global</a>&nbsp;</b>(BEEM), with a market cap of just $276 million, specializes in clean-energy charging equipment for EVs; <a href=\"https://laohu8.com/S/AONE.U\">one</a> of its products uses solar power.</p><p>If you prefer a traditional automaker stock, my top choice is <b>Volkswagen&nbsp;</b>(VWAGY), with a dozen brands from seven European countries, including Audi, Bentley and Porsche, plus the truck and bus companies Scania and MAN. VW sold only half as many EVs as Tesla last year, but the demand in Europe is intense, as it will soon be in the U.S.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disrupters Are Driving the Car Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisrupters Are Driving the Car Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/disrupters-driving-car-market-103000152.html><strong>Kiplinger</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When I was 9, my grandfather gave me a present: my first share of stock. It was a gorgeous, embossed certificate issued by the Ford Motor (F), which had just gone public on January 18, 1956, at $64.50...</p>\n\n<a href=\"https://finance.yahoo.com/news/disrupters-driving-car-market-103000152.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","F":"福特汽车","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/disrupters-driving-car-market-103000152.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2138117769","content_text":"When I was 9, my grandfather gave me a present: my first share of stock. It was a gorgeous, embossed certificate issued by the Ford Motor (F), which had just gone public on January 18, 1956, at $64.50 a share.In 1988, I decided to sell my share, which after splits had become many shares worth $828. Selling at the time turned out to be a good idea. Ford shares peaked in 1999.But don’t count Ford out. The drop in revenues from the pandemic was not as bad as expected, and over the past 12 months, the stock has returned 143%; General Motors (GM) has returned 162%.Ford and GM, two stodgy companies that have been selling pretty much the same product for more than a century, have felt the shock of an earthshaking disruption of their industry. It's a case of respond or die, and the two companies have responded, though a bit late.Disruptive innovation is a term coined in 1995 by Harvard Business School professor Clayton Christensen. Most people use the shorthand disruption to mean a general shake-up in an industry. But Christensen, who died last year, had a more precise definition: \"a process whereby a smaller company with fewer resources is able to successfully challenge established incumbent businesses.\"While the incumbents are focused on gradually improving their products to satisfy traditional customers, disrupters target \"overlooked segments, gaining a foothold,\" Christensen wrote.Incumbents ignore disrupters because those segments are small or unprofitable. The disrupters then expand their offerings, \"delivering the performance that incumbents' mainstream customers require, while preserving the advantages that drove their early success.\" When mainstream customers start adopting the disrupters' products \"in volume,\" you've got real disruption.Tesla: A Model DisrupterA model disrupter. An upstart called Tesla Motors, now just Tesla (TSLA), fits the Christensen model. The company was launched in 2003, released its first plug-in electric car five years later, and went public two years after that. Elon Musk took his earnings as cofounder of PayPal Holdings (PYPL) and became an early investor in Tesla; in 2008, he became CEO.In 2015, when Christensen’s article from which I'm quoting appeared in the Harvard Business Review, Tesla had two models and it sold 50,000 cars. Sales doubled in two years and reached 500,000 in 2020; this year, the forecast is 800,000 vehicles.Tesla is by far the largest global electric vehicle maker, manufacturing four models, including one with a list price of only $40,120. It's working on a beautiful long-haul truck. Holding Tesla back from even more sales this year is a pandemic-induced shortage of microchips, which should be temporary.The incumbents have responded. Last year, Ford said it would invest $11.5 billion in electric vehicles through 2022, producing a zero-emissions Mustang and F-150 truck. In January, GM announced it would phase out petroleum-fueled vehicles and sell only cars and trucks that produce zero emissions.I was not a Tesla believer years ago, but I am now. Tesla is still small ($32 billion in revenues last year, compared with GM's $122 billion) and unprofitable. An investment in Bitcoin and sales of regulatory credits to internal-combustion-engine carmakers saved Tesla from showing a loss in the most recent quarter.Stocks, however, are priced according to expectations, not history, and Tesla's future looks spectacular. In late 2019, Teslas started rolling out of a $2 billion factory in Shanghai, and in April the company announced a $1 billion factory in Austin, Texas.Musk forecasts that Tesla's U.S. market share will rise from 2% today to 10% in 2025, and analysts at Morgan Stanley project that the company's manufacturing capacity will reach 5.5 million vehicles by 2030. That compares favorably with GM's 6.8 million in 2020.Tesla's stock price has become more attractive lately, dropping more than 20% from its January peak, partly because of the chip shortage. Its market capitalization (shares outstanding times price) is $647 billion, or nearly twice as much as GM, Ford and Toyota Motor (TM) combined. In fact, Tesla is the seventh-largest U.S. company by market cap, after five tech giants and Berkshire Hathaway (BRK.B); it's bigger than Walmart (WMT) and JPMorgan Chase (JPM).Is this crazy?I don't think so. The global auto market is estimated to grow to $9 trillion by 2030.11 More Automotive InnovatorsTech is the ignition. Tesla is not the only vehicle disrupter. Technology is front and center in the sector. Small, innovative companies abound, most of them still private. But there are good stocks to buy. One of the largest is the dominant ride-hailing company, Uber (UBER), with a market cap of about $90 billion.SOURCE: MorningstarVeoneer (VNE) is a Swedish company that makes automobile-mounted cameras, systems that assist night driving and other navigation electronics. Sales were hit last year by the pandemic, and the stock trades at less than half its 2018 high.Another attractive Swedish firm, Autoliv (ALV), makes auto-safety systems for the global auto industry. Autoliv has been consistently profitable, with a stock that's up by more than half this year. Aptiv (APTV), an Irish maker of sophisticated vehicle electronics, is also highly profitable, with a $38 billion market cap.Another company with substantial sales and earnings and a commitment to EVs is BYD (BYDDY), based in Shenzhen, China, with a market cap of $60 billion. BYD (an acronym for “Build Your Dreams”) started as a battery maker and now manufactures electric and internal-combustion vehicles; some of its EVs sell for as little as $9,000. Nearly all of Shenzhen’s 20,000 taxis are BYDs. Part of the appeal of BYD: The stock is down 46% since February, despite consistently rising revenues.China is the largest market for EVs, with 1.2 million sales last year. Two other Chinese manufacturers to note are Li Auto (LI), whose niche is SUVs, and the larger XPeng (XPEV), which makes SUVs and a four-door sport sedan; Xpeng is also in the ride-hailing business. Both stocks are well priced, having fallen by half in less than six months.More risky but worth consideration are some early-stage auto-tech firms. Luminar Technologies (LAZR) makes sensors and software that enable autonomous driving. Luminar had only $14 million in sales last year, but its prospects have earned it a market cap of $7 billion.QuantumScape (QS) is a lithium-ion battery maker with no sales in 2020 but a market cap of $12 billion. Beam Global (BEEM), with a market cap of just $276 million, specializes in clean-energy charging equipment for EVs; one of its products uses solar power.If you prefer a traditional automaker stock, my top choice is Volkswagen (VWAGY), with a dozen brands from seven European countries, including Audi, Bentley and Porsche, plus the truck and bus companies Scania and MAN. VW sold only half as many EVs as Tesla last year, but the demand in Europe is intense, as it will soon be in the U.S.","news_type":1},"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198937930,"gmtCreate":1620917706020,"gmtModify":1634195279996,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/198937930","repostId":"1120393789","repostType":4,"repost":{"id":"1120393789","kind":"news","pubTimestamp":1620917058,"share":"https://www.laohu8.com/m/news/1120393789?lang=&edition=full","pubTime":"2021-05-13 22:44","market":"us","language":"en","title":"Lemonade paring market loss after new short call from Muddy Waters","url":"https://stock-news.laohu8.com/highlight/detail?id=1120393789","media":"seekingalpha","summary":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerabilit","content":"<p>Lemonade now&nbsp;up 2%,&nbsp;hours&nbsp;ago,&nbsp;on a&nbsp;short call from Muddy Waters that alleges a securityvulnerability with the company.</p><p><img src=\"https://static.tigerbbs.com/01f8da73a2adc99f0e8f04cc034d6170\" tg-width=\"769\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p><p>Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.</p><p>Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"</p><p>Lemonade didn't immediately respond to Seeking Alpha request for comment.</p><p>Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.</p><p>Lemonadeshort interest 19%of float.</p><p>Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lemonade paring market loss after new short call from Muddy Waters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLemonade paring market loss after new short call from Muddy Waters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially ...</p>\n\n<a href=\"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc."},"source_url":"https://seekingalpha.com/news/3695916-lemonade-falls-on-new-short-call-from-muddy-waters","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1120393789","content_text":"Lemonade now up 2%, hours ago, on a short call from Muddy Waters that alleges a securityvulnerability with the company.Muddy Waters alleges that Lemonade's site has a security flaw that potentially exposes its customers' \"personally identifiable information (\"PII\"), according to theshort report.Muddy Waters Carson Block writes in a letter dated today to Lemonade's CEO asking that the company to take the site offline \"immediately and fix the vulnerability.\"Lemonade didn't immediately respond to Seeking Alpha request for comment.Muddy Waters isn't the first short to target Lemonade. Late last year The Friendly Bearissued a short callon the insurer.Lemonadeshort interest 19%of float.Yesterday,Lemonade stock drops after catastrophe losses fuel Q1 earnings miss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198916846,"gmtCreate":1620918017485,"gmtModify":1634195276168,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/198916846","repostId":"1120393789","repostType":4,"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136950370,"gmtCreate":1621991301790,"gmtModify":1634184929558,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Up up up to the moon","listText":"Up up up to the moon","text":"Up up up to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136950370","repostId":"1159103819","repostType":4,"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184357985,"gmtCreate":1623685969847,"gmtModify":1634030056643,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Nice..","listText":"Nice..","text":"Nice..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/184357985","repostId":"2143800737","repostType":4,"isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136435834,"gmtCreate":1622034952028,"gmtModify":1634184488642,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Like and comment, please&nbsp;","listText":"Like and comment, please&nbsp;","text":"Like and comment, please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/136435834","repostId":"2138110551","repostType":4,"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120952794,"gmtCreate":1624293245018,"gmtModify":1634008220182,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Up up up..","listText":"Up up up..","text":"Up up up..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120952794","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187240224,"gmtCreate":1623756650268,"gmtModify":1634028931120,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Yes all go up","listText":"Yes all go up","text":"Yes all go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187240224","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184357608,"gmtCreate":1623686003204,"gmtModify":1634030056422,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Great 👍","listText":"Great 👍","text":"Great 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184357608","repostId":"1117313016","repostType":4,"repost":{"id":"1117313016","kind":"news","pubTimestamp":1623680913,"share":"https://www.laohu8.com/m/news/1117313016?lang=&edition=full","pubTime":"2021-06-14 22:28","market":"us","language":"en","title":"Corsair Surges Amid Meme Rally; Jim Cramer Warns on High-Level Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=1117313016","media":"thestreet","summary":"Corsair Gaming  -Get Report shares surged higher Monday as the gaming and content equipment-maker appeared to add its name to the list of meme stock favorites.TheStreet's founder Jim Cramer, however, cautioned that such a steep rise for a fundamentally sound stock like Corsair would likely entice large-scale sellers at these levels.\"Corsair is a company I like very much, because it's basically a souped-up Logitech and Logitech's been a great stock\" Cramer told CNBC's Squawk on The Street program","content":"<p>Corsair Gaming&nbsp;(<b>CRSR</b>) -Get Report&nbsp;shares surged higher Monday as the gaming and content equipment-maker appeared to add its name to the list of meme stock favorites.</p>\n<p>Data from theYolosocks.livewebsite, which tracks real-time mentions on stocks within Reddit's r/wallstreetbets chatroom, indicates that Corsair is the second most-discussed stock among users, up from a previous rank of 11, over the past 24 hours and more than 860 mentions.</p>\n<p>TheStreet's founder Jim Cramer, however, cautioned that such a steep rise for a fundamentally sound stock like Corsair would likely entice large-scale sellers at these levels.</p>\n<p>\"Corsair is a company I like very much, because it's basically a souped-up Logitech and Logitech's been a great stock\" Cramer told CNBC's Squawk on The Street program. \"They have the high-performance equipment you need to dominate in e-sports and I think e-sports are here to stay.\"</p>\n<p>\"I don't know why the 'meme' people have a monopoly on whatever they play with,\" Cramer said.&nbsp;\"No Wall Street analyst could move Corsair this much, so for people who've been waiting for the stock to go to $37 and now it's at $41, those people aren't going to turn buyers. They're sellers.\"</p>\n<p>\"The meme people think they're hurting the hedge funds, when in fact they're a tool to the hedge funds,\" Cramer said.</p>\n<p>Corsair shares were marked 19.3% higher in early trading Monday to change hands at $38.60 each -- after hitting a session high of $42.97 at the opening bell -- in a move that bumps the stock's year-to-date gain to around 12%.</p>\n<p>Last month, Corsair posted first quarter earnings of $80 million on revenues of $529 million thanks to surging growth in its gaming nd peripherals business, which saw sales rise by 132% when compared to last year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corsair Surges Amid Meme Rally; Jim Cramer Warns on High-Level Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorsair Surges Amid Meme Rally; Jim Cramer Warns on High-Level Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/corsair-surges-in-latest-meme-rally-jim-cramer-warns-on-sellers><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corsair Gaming (CRSR) -Get Report shares surged higher Monday as the gaming and content equipment-maker appeared to add its name to the list of meme stock favorites.\nData from theYolosocks.livewebsite...</p>\n\n<a href=\"https://www.thestreet.com/investing/corsair-surges-in-latest-meme-rally-jim-cramer-warns-on-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSR":"Corsair Gaming, Inc."},"source_url":"https://www.thestreet.com/investing/corsair-surges-in-latest-meme-rally-jim-cramer-warns-on-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117313016","content_text":"Corsair Gaming (CRSR) -Get Report shares surged higher Monday as the gaming and content equipment-maker appeared to add its name to the list of meme stock favorites.\nData from theYolosocks.livewebsite, which tracks real-time mentions on stocks within Reddit's r/wallstreetbets chatroom, indicates that Corsair is the second most-discussed stock among users, up from a previous rank of 11, over the past 24 hours and more than 860 mentions.\nTheStreet's founder Jim Cramer, however, cautioned that such a steep rise for a fundamentally sound stock like Corsair would likely entice large-scale sellers at these levels.\n\"Corsair is a company I like very much, because it's basically a souped-up Logitech and Logitech's been a great stock\" Cramer told CNBC's Squawk on The Street program. \"They have the high-performance equipment you need to dominate in e-sports and I think e-sports are here to stay.\"\n\"I don't know why the 'meme' people have a monopoly on whatever they play with,\" Cramer said. \"No Wall Street analyst could move Corsair this much, so for people who've been waiting for the stock to go to $37 and now it's at $41, those people aren't going to turn buyers. They're sellers.\"\n\"The meme people think they're hurting the hedge funds, when in fact they're a tool to the hedge funds,\" Cramer said.\nCorsair shares were marked 19.3% higher in early trading Monday to change hands at $38.60 each -- after hitting a session high of $42.97 at the opening bell -- in a move that bumps the stock's year-to-date gain to around 12%.\nLast month, Corsair posted first quarter earnings of $80 million on revenues of $529 million thanks to surging growth in its gaming nd peripherals business, which saw sales rise by 132% when compared to last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184355081,"gmtCreate":1623685874143,"gmtModify":1634030058615,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"hello jiayou all..","listText":"hello jiayou all..","text":"hello jiayou all..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184355081","repostId":"2143738859","repostType":4,"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136492524,"gmtCreate":1622034220168,"gmtModify":1634184496621,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3583498842755651\">@MrWealthy</a>: Up up up to the moon","listText":"//<a href=\"https://laohu8.com/U/3583498842755651\">@MrWealthy</a>: Up up up to the moon","text":"//@MrWealthy: Up up up to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136492524","repostId":"1159103819","repostType":4,"repost":{"id":"1159103819","kind":"news","pubTimestamp":1621990785,"share":"https://www.laohu8.com/m/news/1159103819?lang=&edition=full","pubTime":"2021-05-26 08:59","market":"us","language":"en","title":"AMC Price Target Raised, Sell Rating Affirmed at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=1159103819","media":"The Street","summary":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the the","content":"<blockquote>\n AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n</blockquote>\n<p>AMC Entertainment&nbsp;(<b>AMC</b>) -Get Report&nbsp;shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.</p>\n<p>To be sure, he kept his sell rating.</p>\n<p>AMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.</p>\n<p>As for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.</p>\n<p>AMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.</p>\n<p>In other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.</p>\n<p>AMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"</p>\n<p>AMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.</p>\n<p>AMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.</p>\n<p>On May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Price Target Raised, Sell Rating Affirmed at Citi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Price Target Raised, Sell Rating Affirmed at Citi\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet ...</p>\n\n<a href=\"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159103819","content_text":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.\nTo be sure, he kept his sell rating.\nAMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.\nAs for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.\nAMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.\nIn other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.\nAMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"\nAMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.\nAMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.\nOn May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136953563,"gmtCreate":1621991396152,"gmtModify":1634184927872,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Take on the ride together ....","listText":"Take on the ride together ....","text":"Take on the ride together ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136953563","repostId":"1159103819","repostType":4,"repost":{"id":"1159103819","kind":"news","pubTimestamp":1621990785,"share":"https://www.laohu8.com/m/news/1159103819?lang=&edition=full","pubTime":"2021-05-26 08:59","market":"us","language":"en","title":"AMC Price Target Raised, Sell Rating Affirmed at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=1159103819","media":"The Street","summary":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the the","content":"<blockquote>\n AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n</blockquote>\n<p>AMC Entertainment&nbsp;(<b>AMC</b>) -Get Report&nbsp;shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.</p>\n<p>To be sure, he kept his sell rating.</p>\n<p>AMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.</p>\n<p>As for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.</p>\n<p>AMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.</p>\n<p>In other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.</p>\n<p>AMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"</p>\n<p>AMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.</p>\n<p>AMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.</p>\n<p>On May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Price Target Raised, Sell Rating Affirmed at Citi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Price Target Raised, Sell Rating Affirmed at Citi\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet ...</p>\n\n<a href=\"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.thestreet.com/investing/amc-price-target-raised-sell-rating-affirmed-at-citi","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159103819","content_text":"AMC stock has more than tripled in the past six months as the Reddit crowd has gone gaga for the theater chain.\n\nAMC Entertainment (AMC) -Get Report shares soared after Citi analyst Jason Bazinet nearly doubled his price target on the world’s biggest movie theater chain to $3.70 from $2.\nTo be sure, he kept his sell rating.\nAMC recently traded at $16.23, up 19%. The stock has more than tripled (up 236%) in the past six months, as the Reddit crowd has gone gaga over the meme company.\nAs for Bazinet, he said AMC remains overvalued, Bloomberg reports. The company's \"elevated leverage [represents] an added risk to an uncertain recovery,\" he said.\nAMC got hammered by the pandemic, which still is limiting attendance at its theaters. But the stock price surge has enabled it to raise capital cheaply.\nIn other AMC news,its British cinemas last week recorded their busiest weekof ticket sales since the pandemic began, offsetting the departure of a key investor in the company.\nAMC said its largest shareholder, China-based Wanda Group, had sold its stake in the group \"through normal open market trading to a widely dispersed array of buyers on the New York Stock Exchange.\"\nAMC's U.S. prospects heading into the Memorial Day weekend are also looking brighter, with domestic coronavirus cases falling and vaccinations rising.\nAMC shares gained last Tuesdayalongside other meme stocks as day traders renewed their bets on shares of companies they feel they can collectively move higher.\nOn May 13,AMC said it completed an offeringof 43 million shares. The offering brought AMC $428 million of new capital, before commissions and fees, at an average price of $9.94 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198919992,"gmtCreate":1620917792316,"gmtModify":1634195278750,"author":{"id":"3583498842755651","authorId":"3583498842755651","name":"MrWealthy","avatar":"https://static.tigerbbs.com/f08bc7a620736dde076644e587c9022d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583498842755651","idStr":"3583498842755651"},"themes":[],"htmlText":"Amc bravo","listText":"Amc bravo","text":"Amc bravo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/198919992","repostId":"1186620588","repostType":4,"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}